» Articles » PMID: 29924959

Immunohistochemical Expression of NEDD9, E-cadherin and γ-catenin and Their Prognostic Significance in Pancreatic Ductal Adenocarcinoma (PDAC)

Overview
Specialty General Medicine
Date 2018 Jun 21
PMID 29924959
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Extensive research is being conducted to identify novel diagnostic, predictive and prognostic biomarkers for pancreatic ductal adenocarcinoma (PDAC), as only a few markers have been routinely used so far with limited success. Our aim was to assess the expression of neural precursor cell expressed developmentally down-regulated protein 9 (NEDD9), E-cadherin, and γ-catenin in PDAC in relation to clinicopathological parameters and patient survival. We also investigated if there is a correlation of NEDD9 expression with E-cadherin or γ-catenin. The protein expression was determined by immunohistochemistry in 61 PDAC and 61 samples of normal pancreatic tissue. The log rank test and Kaplan-Meier survival curve were used for survival analysis. E-cadherin and γ-catenin expressions were reduced in PDAC, and completely retained in normal pancreatic tissue. Expression of NEDD9 was significantly increased in PDAC (strong expression in 78.7% of cases and moderate in 21.3%) and reduced in normal pancreatic tissue (strong positivity in 45.9% of cases, moderate in 31.1%, and weak in 23%). There was a positive correlation between reduced E-cadherin and γ-catenin expression in PDAC (p = 0.015). The loss or reduced expression of E-cadherin had a negative impact on patient survival (p = 0.020). A negative correlation between E-cadherin expression and tumor grade was also observed (p = 0.011). Decreased E-cadherin expression was more common in male patients with PDAC (81.3% vs. 60% for females, p = 0.005). γ-catenin and NEDD9 expressions were not statistically correlated with tumor stage and grade, gender, nor with patient survival. Our results support the role of NEDD9, E-cadherin and γ-catenin proteins in PDAC, but further research should clarify in detail their mechanism of action in pancreatic cancer.

Citing Articles

The Prognostic Significance of NEDD9 Expression in Human Cancers: A Systematic Review, Meta-Analysis, and Omics Exploration.

Yasin J, Odat R, Qtaishat F, Tamimi M, Alsufi M, Younis O Technol Cancer Res Treat. 2024; 23:15330338241297597.

PMID: 39540210 PMC: 11561999. DOI: 10.1177/15330338241297597.


Unraveling dynamically encoded latent transcriptomic patterns in pancreatic cancer cells by topic modeling.

Zhang Y, Khalilitousi M, Park Y Cell Genom. 2023; 3(9):100388.

PMID: 37719139 PMC: 10504675. DOI: 10.1016/j.xgen.2023.100388.


Overexpression of Circular RNA circ_0013587 Reverses Erlotinib Resistance in Pancreatic Cancer Cells Through Regulating the miR-1227/E-Cadherin Pathway.

Xu H, Chen R, Shen Q, Yang D, Peng H, Tong J Front Oncol. 2021; 11:754146.

PMID: 34552882 PMC: 8450525. DOI: 10.3389/fonc.2021.754146.


MicroRNA-1252-5p, regulated by Myb, inhibits invasion and epithelial-mesenchymal transition of pancreatic cancer cells by targeting NEDD9.

Xue Y, Wu T, Sheng Y, Zhong Y, Hu B, Bao C Aging (Albany NY). 2021; 13(14):18924-18945.

PMID: 34314382 PMC: 8351675. DOI: 10.18632/aging.203344.


Prognostic and Clinicopathological Significance of E-Cadherin in Pancreatic Cancer Patients: A Meta-Analysis.

Wang P, Zhu Z Front Oncol. 2021; 11:627116.

PMID: 33912451 PMC: 8074677. DOI: 10.3389/fonc.2021.627116.


References
1.
Nagathihalli N, Merchant N . Src-mediated regulation of E-cadherin and EMT in pancreatic cancer. Front Biosci (Landmark Ed). 2012; 17(6):2059-69. DOI: 10.2741/4037. View

2.
Hsu H, Shan Y, Jin Y, Lai M, Lin P . Loss of E-cadherin and beta-catenin is correlated with poor prognosis of ampullary neoplasms. J Surg Oncol. 2010; 101(5):356-62. DOI: 10.1002/jso.21493. View

3.
Yin T, Getsios S, Caldelari R, Kowalczyk A, Muller E, Jones J . Plakoglobin suppresses keratinocyte motility through both cell-cell adhesion-dependent and -independent mechanisms. Proc Natl Acad Sci U S A. 2005; 102(15):5420-5. PMC: 556221. DOI: 10.1073/pnas.0501676102. View

4.
Xue Y, Sheng Y, Liu Z, Wei Z, Cao H, Wu Y . Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance. Tumour Biol. 2012; 34(2):895-9. DOI: 10.1007/s13277-012-0624-8. View

5.
Lupu-Meiri M, Geras-Raaka E, Lupu R, Shapira H, Sandbank J, Segal L . Knock-down of plasminogen-activator inhibitor-1 enhances expression of E-cadherin and promotes epithelial differentiation of human pancreatic adenocarcinoma cells. J Cell Physiol. 2012; 227(11):3621-8. PMC: 3469200. DOI: 10.1002/jcp.24068. View